Recent Updates
Recently added Catalysts

Bazedoxifene and conjugated estrogens

Phase 3

Endometrial Hyperplasia | Small molecule | Oncology |Pfizer, Inc.|Trials Updated: May 1, 2015

Bazedoxifene and conjugated estrogens development status

Highest phase Phase 3
Registered trials 1 across 1 sponsor since Jun 2008

Bazedoxifene and conjugated estrogens target and mechanism

Molecular targetESR2, ESR1
Target classModulator
ModalitySmall molecule

Also known as Bazedoxifene, Bazedoxifene Acetate, Bazedoxifene Acetate (TSE-424)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials14
Total Enrollment17,340

FDA Designations

No designations recorded

Bazedoxifene and conjugated estrogens clinical trials

Bazedoxifene and conjugated estrogens · 14 trials · 7 indications

Phase 3 7Phase 2 1Phase 1 6
NCT00808132Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal OsteoporosisMenopause
COMPLETED1,886 Analytics
NCT00234819Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With MenopauseVasomotor Symptoms Associated With Menopause
COMPLETED325 Analytics
NCT00238732Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With MenopauseVaginal Atrophy
COMPLETED650 Analytics
NCT00242710Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal WomenEndometrial Hyperplasia
COMPLETED1,083 Analytics
NCT00675688Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal WomenEndometrial Hyperplasia
COMPLETED3,544 Analytics
NCT00205777Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal WomenOsteoporosis
COMPLETED7,609 Analytics
NCT00481169Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal WomenOsteoporosis
COMPLETED1,742 Analytics
PHASE3COMPLETED
Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis
MenopauseUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
Vasomotor Symptoms Associated With MenopauseUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Vasomotor Symptoms Associated With Menopause
Vaginal AtrophyUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women
Endometrial HyperplasiaUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
Endometrial HyperplasiaUnlock trial analytics
PHASE3COMPLETED
Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women
OsteoporosisUnlock trial analytics
PHASE3COMPLETED
Study Evaluating TSE-424/Placebo/Raloxifene in Preventing Osteoporosis in Postmenopausal Women
OsteoporosisUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study
Month 12

Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. If both the pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted. Results were summarized for two definitions of hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia); definition 1: participants were considered to have a diagnosis of hyperplasia when the 3 pathologists disagreed but at least 1 pathologist determined hyperplasia; definition 2: participants were considered to have a diagnosis of hyperplasia if at least 2 of the 3 pathologists agreed on the diagnosis.

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12: Osteoporosis Sub-Study
Baseline, Month 12

BMD measurements of the anteroposterior lumbar spine were acquired by using dual-energy x-ray absorptiometry (DXA) scans, twice at Month 12 for a subset of participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. Mean percentage change from baseline of the 2 readings were reported.

Number and severity of moderate and severe hot flashes at week 4 and at week 12, as reported daily on subject diary cards.
Superficial cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
Parabasal cells (by cervical/vaginal cytologic smear) at screening, and weeks 4 and 12.
Percentage of Participants With Hyperplasia at Screening
Screening

Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.

Percentage of Participants With Hyperplasia at Month 12
Month 12

Endometrial hyperplasia was assessed by endometrial biopsies. All endometrial biopsies were read centrally by 2 primary pathologists. Participants were considered to have a diagnosis of hyperplasia if both pathologists read hyperplasia (simple hyperplasia with or without atypia or complex hyperplasia with or without atypia). If the both pathologists disagreed on the presence of hyperplasia, a third pathologist was consulted, with the final diagnosis determined by the majority opinion.

Bone Mineral Density (BMD) of Lumbar Spine at Screening
Screening

BMD measurements of the anteroposterior lumbar spine were acquired by dual-energy x-ray absorptiometry (DXA), twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12
Baseline, Month 12

BMD measurements of the anteroposterior lumbar spine were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.

Bone Mineral Density (BMD) of Total Hip at Screening
Screening

BMD measurements of the total hip were acquired by DXA, twice during screening in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.

Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 12
Baseline, Month 12

BMD measurements of the total hip were acquired by DXA, twice at Month 12 in participants who entered the osteoporosis substudy. The second scan was to be performed on the same day as the first; however, the participant was to be removed completely from the table after the first scan and repositioned for the second scan. An average of the 2 readings was reported.

To evaluate the effects of Bazedoxifene/Conjugate Estrogens (CE) combinations on the incidence of endometrial hyperplasia in postmenopausal women.
one year
Percentage of Participants With New Vertebral Fractures Through Month 36
Baseline through Month 36

New vertebral fracture: decrease in anterior, mid, or posterior vertebral (vt) height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

Percentage of Participants With New Vertebral Fractures Through Month 60
Baseline through Month 60

New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

Percentage of Participants With New Vertebral Fractures Through Month 84
Baseline through Month 84

New vertebral fracture: decrease in anterior, mid, or posterior vt height of approximately 20% and 4 millimeter (mm) or more from baseline (base) to end of study confirmed by measurement of involved vt body, a semi-quantitative grade change of 1 from base for any vertebra from fourth thoracic to fourth lumbar vertebra (T4 to L4), provided vertebra was not fractured at base. Participant was counted only once irrespective of how many new vt fractures were diagnosed. Stratification factor was base fracture status, categorized as no prevalent fracture and at least 1 prevalent fracture.

The percent change from baseline in lumbar spine bone mineral density (BMD) after 24 months.
24 months
Bone mineral density of lumbar spine (L1-L4) at 2 years.
To evaluate the potential pharmacokinetic (PK) interaction of multiple oral doses of bazedoxifene (BZA) and a single dose of conjugated estrogens (CE) when co administered to healthy postmenopausal women.
3 months
The plasma concentration data and pharmacokinetic (PK) parameters of BZA and CE.
Pharmacokinetic analyses.
PK results
Pharmacokinetic measures of blood levels of endogenous estrogen hormones, conjugated estrogens and bazedoxifene.

Secondary Endpoints

Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 6: Osteoporosis Sub-Study
Baseline, Month 6
Percent Change From Baseline in Bone Mineral Density (BMD) of Total Hip at Month 6, 12: Osteoporosis Sub-Study
Baseline, Month 6, Month 12
Percentage of Participants With Cumulative Amenorrhea: Main Study
Day 1 up to Day 364
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALbazedoxifene 20 mg/conjugated estrogens 0.45 mg
2EXPERIMENTALbazedoxifene 20 mg/conjugated estrogens 0.625 mg
3EXPERIMENTALbazedoxifene 20 mg
4ACTIVE_COMPARATORPrempro
5PLACEBO_COMPARATORPlacebo
Arm 2EXPERIMENTALBZA 20mg/CE 0.45
Arm 3ACTIVE_COMPARATORCE 0.45mg/MPA1.5mg
Arm 4PLACEBO_COMPARATORPlacebo
AEXPERIMENTAL -
BACTIVE_COMPARATOR -
CPLACEBO_COMPARATOR -

Interventions

NameTypeDescription
bazedoxifene 20 mg/ conjugated estrogens 0.45 mgDRUGOne capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
bazedoxifene 20 mg/ conjugated estrogens 0.625 mgDRUGOne capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
bazedoxifene 20 mgDRUGOne capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mgDRUGOne capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
PlaceboDRUGOne capsule, placebo (over-encapsulated), once a day for one year.
Bazedoxifene/Conjugated EstrogenDRUG -
CE 0.45 mg/MPA 1.5mgDRUGSubjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
Bazedoxifene/Conjugate Estrogens (CE)DRUG -
RaloxifeneDRUG -
Bazedoxifene AcetateDRUGBZA 20mg, daily, oral
Bazedoxifene Acetate (TSE-424)DRUG -
BazedoxifeneDRUG -
Bazedoxifene and conjugated estrogensDRUGBazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
Bazedoxifene/Conjugated EstrogensDEVICE -
Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tabletDRUG -
bazedoxifene/conjugated estrogens combination tabletDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range40 Years to 64 Years
SexFEMALE
Healthy VolunteersNo
Study Sites178

Inclusion Criteria: * Generally healthy, postmenopausal women, aged 40 to 64 seeking treatment for menopausal symptoms * At least 12 months of spontaneous amenorrhea, OR 6 months spontaneous amenorrhea with follicle-stimulating hormone (FSH) levels \> 40 mIU/mL * Intact Uterus Exclusion Criteria: ...

Countries:United StatesArgentinaAustraliaChileColombiaDenmarkFinlandHungaryMexicoNew ZealandNorwayPolandAustriaBelgiumBrazilBulgariaCanadaCroatiaEstoniaFranceGermanyGreeceHong KongItalyLithuaniaNetherlandsRomaniaRussiaSlovakiaSouth AfricaSpain
Unlock Eligibility Criteria

Frequently asked questions about Bazedoxifene and conjugated estrogens

What is bazedoxifene and conjugated estrogens?

Bazedoxifene and conjugated estrogens is a small molecule combination therapy developed by Pfizer (PFE) for postmenopausal women. It pairs bazedoxifene acetate with conjugated estrogens and has been studied in Phase 3 trials for menopause, osteoporosis, endometrial hyperplasia, and vaginal atrophy.

What is bazedoxifene and conjugated estrogens used for?

Bazedoxifene and conjugated estrogens is used for conditions affecting postmenopausal women, including menopause, postmenopausal osteoporosis, osteoporosis, endometrial hyperplasia, and vaginal atrophy. It is a combination tablet containing bazedoxifene acetate and conjugated estrogens.

What does bazedoxifene and conjugated estrogens target?

Bazedoxifene and conjugated estrogens targets the estrogen receptors ESR1 and ESR2. Bazedoxifene acts as a modulator of these receptors, while the conjugated estrogens component provides estrogenic activity, together forming a combined estrogen and selective estrogen receptor modulator approach.

Who makes bazedoxifene and conjugated estrogens?

Bazedoxifene and conjugated estrogens is developed by Pfizer, Inc., which trades under the ticker PFE. Pfizer is the company behind the bazedoxifene/conjugated estrogens combination tablet.

What phase is bazedoxifene and conjugated estrogens in?

Bazedoxifene and conjugated estrogens is in Phase 3 development. Four clinical trials have been completed, including Phase 3 and Phase 1 studies, with no active trials currently ongoing. It is an investigational combination therapy.

What clinical trials is bazedoxifene and conjugated estrogens in?

Bazedoxifene and conjugated estrogens has been evaluated in completed trials including NCT00808132, a Phase 3 study of endometrial safety and postmenopausal osteoporosis; NCT00675688, a Phase 3 safety and efficacy study; NCT00706225, a Phase 1 drug interaction study; and NCT00550433, a Phase 1 study in postmenopausal women.

Is bazedoxifene and conjugated estrogens the same as bazedoxifene?

No, bazedoxifene and conjugated estrogens is a combination product containing both bazedoxifene acetate and conjugated estrogens. Bazedoxifene alone is a separate component. The combination is also known as bazedoxifene/conjugated estrogens combination tablet and bazedoxifene 20 mg/conjugated estrogens 0.45 mg.